Cargando…

CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway

Prostate cancer (PCa) endangers the life and health of older men. Most PCa cases develop into castration-resistant PCa (CRPC) within 2 years. At present, the molecular mechanisms of the occurrence and development of PCa and its transformation to CRPC remain unknown. The present study aimed to invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Linjin, Hu, Yiren, Chen, Dake, Zhu, Jianlong, Bao, Wenshuo, Xu, Xiaomin, Chen, Heyi, Chen, Wu, Feng, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628290/ https://www.ncbi.nlm.nih.gov/pubmed/34791506 http://dx.doi.org/10.3892/mmr.2021.12533

Ejemplares similares

Long-term outcomes of radiofrequency ablation vs. partial nephrectomy for cT1 renal cancer: A meta-analysis and systematic review
por: Li, Linjin, et al.
Publicado: (2023)

CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling
por: Xu, Gang, et al.
Publicado: (2017)

CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells
por: Yuan, Yeqing, et al.
Publicado: (2020)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
por: Chen, Zhi, et al.
Publicado: (2021)

The Role of Polymorphisms in Genes of PI3K/Akt Signaling Pathway on Prostate
por: Xu, Wei, et al.
Publicado: (2019)

LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway
por: Zhang, Xiaowen, et al.
Publicado: (2022)

Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway
por: Shao, Jingwei, et al.
Publicado: (2017)

TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway
por: Lu, Qiang, et al.
Publicado: (2016)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma
por: Jiang, Fengqi, et al.
Publicado: (2021)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance
por: Chang, Kwang-Yu, et al.
Publicado: (2013)

PSMC4 promotes prostate carcinoma progression by regulating the CBX3–EGFR‐PI3K‐AKT‐mTOR pathway
por: Liu, Kaifeng, et al.
Publicado: (2023)

Sasanquasaponin inhibited epithelial to mesenchymal transition in prostate cancer by regulating the PI3K/Akt/mTOR and Smad pathways
por: Li, Wenfeng, et al.
Publicado: (2022)

Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways
por: Chen, Yu-An, et al.
Publicado: (2018)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer
por: Su, Wei, et al.
Publicado: (2016)

SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway
por: Quan, Yizhou, et al.
Publicado: (2015)

CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation
por: Liu, Baocai, et al.
Publicado: (2015)

SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)

METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner
por: Shi, Yuntao, et al.
Publicado: (2020)

Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells
por: Chen, Ruiqui, et al.
Publicado: (2017)

The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway
por: Zhao, Wen-Tao, et al.
Publicado: (2021)

Small‐molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual‐inhibiting properties for bladder cancer treatment
por: Li, Guoyin, et al.
Publicado: (2023)

SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer
por: Xiao, Zhao-Ming, et al.
Publicado: (2021)

Overexpression of IGFBP5 Enhances Radiosensitivity Through PI3K-AKT Pathway in Prostate Cancer
por: Chen, Xue, et al.
Publicado: (2020)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
por: Chen, Zhao-Hui, et al.
Publicado: (2023)

Astilbin-induced inhibition of the PI3K/AKT signaling pathway decelerates the progression of osteoarthritis
por: Chen, Chunlin, et al.
Publicado: (2020)

JMJD8 Promotes Malignant Progression of Lung Cancer by Maintaining EGFR Stability and EGFR/PI3K/AKT Pathway Activation
por: Zhang, Bo, et al.
Publicado: (2021)

CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
por: Yuan, Wanqiong, et al.
Publicado: (2021)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

[6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling
por: Jiang, Xueyi, et al.
Publicado: (2021)

AB179. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells
por: Hu, Fengzhan, et al.
Publicado: (2015)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Correction: Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells
por: Chen, Ruiqi, et al.
Publicado: (2018)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways
por: Pi, Jiang, et al.
Publicado: (2017)

Cryptotanshinone Inhibites Bladder Cancer Cell Proliferation and Promotes Apoptosis via the PTEN/PI3K/AKT Pathway
por: Liu, Yadong, et al.
Publicado: (2020)

CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway
por: Liu, Fu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6bpsv783p1gn7r6k9tlqq1th3s